Merck KGaA reports higher profits on strong volumes across its businesses
Company expects strong organic growth in sales, EBITDA in 2022
Company expects strong organic growth in sales, EBITDA in 2022
Serina has over 17 years of experience in the biopharmaceutical industry
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
Thermo Fisher and Symphogen extend their collaboration using innovative and efficient workflows to improve data confidence, aiding the creation of new cancer treatments
Collaboration in the industry needs to be institutionalised to drive the growth.
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
The facility will manufacture its Herceptin biosimilar, Tuznue
Essential products manufactured by Sartorius, using Sü dpack polymer films made from Dow resins, support safe and effective vaccine production for global vaccine supply
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
Subscribe To Our Newsletter & Stay Updated